Joseph J. LaRosa
General Counsel
Regeneron Pharmaceuticals, Inc. (REGN)Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Joseph J. LaRosa
Joseph J. LaRosa is recorded as General Counsel at Regeneron Pharmaceuticals, Inc. (REGN). The proxy statement of Regeneron Pharmaceuticals, Inc. reports total compensation of $7,458,970 for Joseph J. LaRosa in fiscal 2025, including a base salary of $916,062. Disclosed compensation is on record for 2 fiscal years. Joseph J. LaRosa has spoken on 1 investor event across 1 company, most recently for Regeneron Pharmaceuticals, Inc. on June 12, 2026.
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Current
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at Regeneron Pharmaceuticals, Inc.
Other people whose current roles at this company are on record from its filings.
- George D. Yancopoulos, M.D., Ph.D. Chairman
- Leonard S. Schleifer, M.D., Ph.D. Chairman
- Christine A. Poon Board Member
- Craig B. Thompson, M.D. Board Member
- David P. Schenkein Board Member
- David P. Schenkein, M.D. Board Member
- Huda Y. Zoghbi, M.D. Board Member
- Joseph L. Goldstein, M.D. Board Member
- Kathryn Guarini Board Member
- Kathryn Guarini, Ph.D. Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Regeneron Pharmaceuticals, Inc. (REGN) | Executive Vice President, General Counsel and Secretary10 | $916,062 | $7,458,970 |
| 2021 | Regeneron Pharmaceuticals, Inc. (REGN) | Executive Vice President, General Counsel and Secretary | $810,000 | $7,126,901 |
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.